시장보고서
상품코드
1466820

세계의 각막 윤부 줄기세포 결핍증(LSCD) 시장 : 주요 조사(KOL 인사이트) - 시장 정보, 역학 및 시장 예측(-2034년)

Limbal Stem Cell Deficiency (LSCD) | Primary Research (KOL´s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034

발행일: | 리서치사: Mellalta Meets LLP | 페이지 정보: 영문 156 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

각막 윤부 줄기세포 결핍증(LSCD, Limbal Stem Cell Deficiency) 시장은 윤부 조직 이식과 같은 조직 기반 기술에 의해 크게 기여하고 있습니다. 2034년까지 새로운 신흥 치료법의 도입은 각막 윤부 줄기세포 결핍증(LSCD) 치료제 시장에 급격한 변화를 가져오는 주요 전환점이 될 것입니다. 조사 대상 국가(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)에 대한 각막 윤부 줄기세포 결핍증(LSCD) 시장 규모는 2020-2034년 조사 기간 중에 22.60%의 CAGR로 고성장을 2034년까지 17억 달러에 달할 것으로 예측됩니다.

각막 윤부 줄기세포 결핍증(LSCD)은 각막 상피 줄기세포/전구세포의 기능 장애로 각막 상피의 정상적인 항상성을 유지할 수 없는 임상 상태를 말합니다.

이러한 세포는 여러 가지 과정에 의해 손상될 수 있으며, 윤부 줄기세포의 손실은 각막 상피 세포를 결막 상피 세포로 대체하여 각막의 정상적인 선명도를 떨어뜨리고 치유 장애, 흉터 및 시력 상실로 이어질 수 있습니다.

상피 불안정성은 질병 과정의 특징으로, 상피가 반복적으로 파괴되고 지속적인 상피 결손이 형성될 수 있습니다. 지속적인 상피 결손이 반복적으로 발생하면 기저 기질에 영향을 미쳐 흉터가 생기거나 해결되지 않는 경우 무균 용융이 발생할 수 있습니다.

세계의 각막 윤부 줄기세포 결핍증(LSCD, Limbal Stem Cell Deficiency) 시장을 조사했으며, 시장 현재 상황/질병 개요 및 치료법/환자 동향/지역별 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 각막 윤부 줄기세포 결핍증(LSCD) 질환의 배경

  • 각막 윤부 줄기세포 결핍증(LSCD)의 소개
  • 각막 윤부 줄기세포 결핍증(LSCD)의 단계
  • 징후 및 증상
  • 각막 윤부 줄기세포 결핍증(LSCD)의 원인 및 위험 요인
  • 각막 윤부 줄기세포 결핍증(LSCD)의 병태
  • 각막 윤부 줄기세포 결핍증(LSCD)의 발병 기전

제3장 각막 윤부 줄기세포 결핍증(LSCD)의 진단

  • 각막 윤부 줄기세포 결핍증(LSCD)의 진단
  • 각막 윤부 줄기세포 결핍증(LSCD) 진단 알고리즘
  • 각막 윤부 줄기세포 결핍증(LSCD)의 진단을 확인하는 데 사용되는 진단 도구

제4장 역학 및 환자 개요

  • 주요 조사 결과
  • 방법 및 데이터 소스
  • 각막 윤부 줄기세포 결핍증(LSCD) 역학 및 모델 매개 변수의 주요 정보원
    • 미국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
    • 일본

제5장 현재의 치료법 및 의료 행위

제6장 각막 윤부 줄기세포 결핍증(LSCD) 환자 동향

제7장 미국, EU4, 영국, 일본에서 미충족 요구

제8장 출시가 끝난 치료법

  • Holoclar(Chiesi Farmaceutici/Holostem Terapie Avanzate)
  • Nepic(Japan Tissue Engineering)
  • Ocural(Japan Tissue Engineering)
  • Sakracy(Hirosaki Lifescience Innovation)

제9장 새로운 치료법

  • 주요 조사 결과
  • 파이프라인 개요
  • 각막 윤부 줄기세포 결핍증(LSCD) 부문에서 주목할만한 진전

제10장 각막 윤부 줄기세포 결핍증(LSCD)의 처방 패턴

제11장 각막 윤부 줄기세포 결핍증(LSCD)-가격 설정 및 상환

제12장 향후 치료 패러다임

제13장 현행 및 신규 치료의 연간 비용

제14장 각막 윤부 줄기세포 결핍증(LSCD)에서 후기 치료의 전략적 검토

제15장 시장 전망

  • 주요 조사 결과
  • 개요
  • 국가별 시장 예측(-2034년)

제16장 국가별 시장 예측

  • 미국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제17장 시장 성장 촉진 및 억제요인

제18장 부록

LYJ

The Limbal Stem Cell Deficiency (LSCD) market is hugely contributed by tissue-based techniques like limbal tissue transplantation. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the Limbal Stem Cell Deficiency (LSCD) therapeutics market. The sales of the emerging therapies for the treatment Limbal Stem Cell Deficiency (LSCD) in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2034 study period, adding a value estimated at a total market of $1.7 Billion by 2034.

"Experts believes that the advent of alternative stem cell sources like MSCs and iPSCs heralds a significant shift toward personalized and regenerative therapies in the LSCD market."

Limbal stem cell deficiency (LSCD) describes the clinical condition when there is dysfunction of the corneal epithelial stem/progenitor cells and the inability to sustain the normal homeostasis of the corneal epithelium.

These cells can be damaged by several different processes and the loss of limbal stem cells results in the replacement of corneal epithelial cells with conjunctival epithelial cells, decreasing the normal clarity of the cornea and leading to impaired healing, scarring and vision loss.

Epithelial instability is a hallmark of the disease process, which can lead to repeated breakdown of the epithelium and the formation of persistent epithelial defects. Recurrent episodes of persistent epithelial defects can affect the underlying stroma, leading to scarring or sterile melts in non-resolving cases.

Mellalta's Limbal Stem Cell Deficiency (LSCD) Report- Market Summary

Market Size 2034: $1.7 billion

CAGR%: 22.60%

Key Market Players: KALA BIO; Claris Biotherapeutics

Forecast Period: 2020-2034

Countries Covered: US, France, Germany, Italy, Spain, UK, China, and Japan.

Current SOC: Limbal tissue transplantation

Future SOC: Hepatocyte Growth Factor (HGF)

Key Unmet Need: Geographical Limitations in Treatment Availability; Conventional Therapies Offer Only Temporary Solutions

Key Insights: Regulatory Challenges have been significant in the advancement of stem cell therapies for LSCD

Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options

Mellalta's Limbal Stem Cell Deficiency (LSCD) Report - Epidemiology

The total prevalent cases of Limbal Stem Cell Deficiency (LSCD) in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). In the United States, the number of individuals living with LSCD is expected to rise to 74,191 by 2034, following a CAGR of 0.8%. As per estimates, the United States will present with the highest prevalence of Limbal Stem Cell Deficiency (LSCD) cases in 2034. Among the EU5, Germany had the highest Limbal Stem Cell Deficiency (LSCD) cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States.

Mellalta's Limbal Stem Cell Deficiency (LSCD) Report - Current Market Size & Forecast Trends

The Limbal Stem Cell Deficiency (LSCD) therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034) to USD 1.7 billion. The United States captured the highest market share as compared to the European 5 countries and Japan.

The current standard of care is limited to tissue-based techniques such as limbal tissue transplantation to address LSCD. However, this traditional approach has several disadvantages. Firstly, it requires a substantial amount of healthy limbal tissue, which poses a risk of causing iatrogenic LSCD in the donor eye. Secondly, when the donor limbal tissue is from a living related or cadaveric donor, potent immunosuppression is required to prevent rejection and subsequent failure of the transplanted tissue. This poses challenges for patients, as lifelong immunosuppression can lead to potential risks such as infection or malignancy and may deter some patients from undergoing the procedure.

In the evolving landscape of LSCD management, stem cell-based therapies have emerged as frontrunners, revolutionizing treatment paradigms. Spearheaded by pioneering products like Holoclar, Nepic, Ocural, and Sakracy, these innovative treatments offer new hope to patients suffering from severe ocular surface disorders. Stem cell therapies, by harnessing the regenerative power of limbal epithelial cells, signify a paradigm shift from conventional treatments, offering a sustainable solution to the challenges of LSCD.

In the 2024-2034 forecast period, the market is set to undergo transformative growth with the anticipated entry of new therapies like KPI012 (KALA BIO) and CSB-001 (Claris Biotherapeutics) and others. The emerging therapies will likely replace existing treatments, reflecting a dynamic shift towards more advanced therapeutic options in the LSCD space and more.

Questions Answered

What is the size of clinically and commercially relevant drug-treatable Limbal Stem Cell Deficiency (LSCD) populations, and how will drug-treatment rates change over time?

Potential challenges and opportunities in implementing approved therapy for Limbal Stem Cell Deficiency (LSCD).

What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?

What key drivers and constraints will affect the Limbal Stem Cell Deficiency (LSCD) therapy market over the forecast period?

Report Highlights

Limbal Stem Cell Deficiency (LSCD) - Current Market Trends

Limbal Stem Cell Deficiency (LSCD) - Current & Forecasted Cases across the G7 Countries

Limbal Stem Cell Deficiency (LSCD) - Market Opportunities and Sales Potential for Agents

Limbal Stem Cell Deficiency (LSCD) - Patient-based Market Forecast to 2034

Limbal Stem Cell Deficiency (LSCD) - Untapped Business Opportunities

Limbal Stem Cell Deficiency (LSCD) - Product Positioning Vis-a-vis Competitors' Products

Limbal Stem Cell Deficiency (LSCD) - KOLs Insight

Table of Content

1.Executive Summary

  • 1.1.Key Findings
  • 1.2.Key Market Challenges and Opportunities
  • 1.3.What Do the Experts Say?

2.Limbal Stem Cell Deficiency (LSCD) Disease Background

  • 2.1.Limbal Stem Cell Deficiency (LSCD) Introduction
  • 2.2.Stages of Limbal Stem Cell Deficiency (LSCD)
  • 2.3.Sign & Symptoms
  • 2.4.Causes and Risk factors of Limbal Stem Cell Deficiency (LSCD)
  • 2.5.Pathogenesis of Limbal Stem Cell Deficiency (LSCD)
  • 2.6.Etiology of limbal stem cell deficiency (LSCD)

3.Limbal Stem Cell Deficiency (LSCD) Diagnosis

  • 3.1.Diagnosis of Limbal Stem Cell Deficiency (LSCD)
  • 3.2.Limbal Stem Cell Deficiency (LSCD) Diagnostic Algorithm
  • 3.3.Diagnostic Tools used to confirm the diagnosis of Limbal Stem Cell Deficiency

4.Epidemiology and Patient Populations

  • 4.1.Key Findings
  • 4.2.Methods and data Sources
    • 4.2.1.Country Specific Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
    • 4.2.2.Country Specific Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
    • 4.2.3.Country Specific Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)
  • 4.3.Key Sources for Limbal Stem Cell Deficiency (LSCD) Epidemiology and Model Parameters
    • 4.3.1.United States
      • 4.3.1.1.United States Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
      • 4.3.1.2.United States Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
      • 4.3.1.3.United States Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)
    • 4.3.2.Germany
      • 4.3.2.1.Germany Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
      • 4.3.2.2.Germany Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
      • 4.3.2.3.Germany Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)
    • 4.3.3.France
      • 4.3.3.1.France Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
      • 4.3.3.2.France Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
      • 4.3.3.3.France Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)
    • 4.3.4.Italy
      • 4.3.4.1.Italy Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
      • 4.3.4.2.Italy Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
      • 4.3.4.3.Italy Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)
    • 4.3.5.Spain
      • 4.3.5.1.Spain Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
      • 4.3.5.2.Spain Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
      • 4.3.5.3.Spain Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)
    • 4.3.6.United Kingdom
      • 4.3.6.1.United Kingdom Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
      • 4.3.6.2.United Kingdom Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
      • 4.3.6.3.United Kingdom Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)
    • 4.3.7.Japan
      • 4.3.7.1.Japan Prevalent cases of Limbal Stem Cell Deficiency (LSCD)
      • 4.3.7.2.Japan Prevalent cases of Limbal Stem Cell Deficiency (LSCD) by Stages
      • 4.3.7.3.Japan Diagnosed and Treated cases of Limbal Stem Cell Deficiency (LSCD)

5.Current Therapies and Medical Practice

  • 5.1.Treatment and Medical Practices of Limbal Stem Cell Deficiency (LSCD)
  • 5.2.Stem Cell Based Therapies in LSCD
  • 5.3.Strategic Product Positioning in the Limbal Stem Cell Deficiency (LSCD) Treatment Landscape: A 10-Year Outlook
  • 5.4.Expert Opinions on Interventional Management

6.Patient Journey in Limbal Stem Cell Deficiency (LSCD)

  • 6.1.Referral Routes
  • 6.2.Diagnosis Evaluation
  • 6.3.Treatment Evaluation
  • 6.4.Factors influencing choice of treatment modality for CLET.

7.Unmet Needs in US, EU4, UK, and JP

8.Marketed Therapies Chapters

  • 8.1.Holoclar (Chiesi Farmaceutici/Holostem Terapie Avanzate)
    • 8.1.1.Product Profile
    • 8.1.2.Clinical Development
    • 8.1.3.Market & Sales Opportunity Forecasted to 2034
  • 8.2.Nepic (Japan Tissue Engineering)
    • 8.2.1.Product Profile
    • 8.2.2.Clinical Development
    • 8.2.3.Market & Sales Opportunity Forecasted to 2034
  • 8.3.Ocural (Japan Tissue Engineering)
    • 8.3.1.Product Profile
    • 8.3.2.Clinical Development
    • 8.3.3.Market & Sales Opportunity Forecasted to 2034
  • 8.4.Sakracy (Hirosaki Lifescience Innovation)
    • 8.4.1.Product Profile
    • 8.4.2.Clinical Development
    • 8.4.3.Market & Sales Opportunity Forecasted to 2034

9.Emerging Therapies

  • 9.1.Key Findings
  • 9.2.Pipeline Overview
  • 9.3.Notable Developments in the Limbal Stem Cell Deficiency (LSCD) space
    • 9.3.1.Product Analysis
      • 9.3.1.1.KPI-012 (KALA BIO)
        • 9.3.1.1.1.Product Profile
        • 9.3.1.1.2.Clinical Development
        • 9.3.1.1.3.Market & Sales Opportunity Forecasted to 2034
      • 9.3.1.2.CSB-001 (Claris Biotherapeutics)
        • 9.3.1.2.1.Product Profile
        • 9.3.1.2.2.Clinical Development
        • 9.3.1.2.3.Market & Sales Opportunity Forecasted to 2034
      • 9.3.1.3.Not Exhaustive list (more drugs are covered..)

10.Prescription Pattern in Limbal Stem Cell Deficiency (LSCD)

11.Limbal Stem Cell Deficiency (LSCD) - Pricing & Reimbursement

  • 11.1.Holoclar Pricing and Reimbursement
  • 11.2.Nepic Pricing and Reimbursement
  • 11.3.Ocural Pricing and Reimbursement
  • 11.4.Sakracy Pricing and Reimbursement

12.Future Treatment Paradigm

  • 12.1.Limbal Stem Cell Deficiency (LSCD) Competitor Landscape and Approvals Anticipated
  • 12.2.Future Treatment Algorithms and Competitor Positioning
  • 12.3.Key Data Summary for Emerging Treatment

13.Annual Cost of Current & Emerging Treatment

14.Late Phase Therapies Strategic Considerations in Limbal Stem Cell Deficiency (LSCD)

15.Market Outlook

  • 15.1.Key Findings
  • 15.2.Overview
  • 15.3.Country Specific Market Forecast to 2034
    • 15.3.1.Country Specific Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 15.3.2.Country Specific Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)

16.Market Forecast by Country

  • 16.1.United States
    • 16.1.1.United States Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 16.1.2.United States Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)
  • 16.2.Germany
    • 16.2.1.Germany Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 16.2.2.Germany Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)
  • 16.3.France
    • 16.3.1.France Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 16.3.2.France Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)
  • 16.4.Italy
    • 16.4.1.Italy Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 16.4.2.Italy Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)
  • 16.5.Spain
    • 16.5.1.Spain Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 16.5.2.Spain Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)
  • 16.6.United Kingdom
    • 16.6.1.United Kingdom Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 16.6.2.United Kingdom Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)
  • 16.7.Japan
    • 16.7.1.Japan Market for Limbal Stem Cell Deficiency (LSCD) 2019-2034 (USD Million)
    • 16.7.2.Japan Market for Limbal Stem Cell Deficiency (LSCD) by Therapies 2019-2034 (USD Million)

17.Market Drivers and Constraints

    • 17.1.1.What Factors Are Driving the Market for Limbal Stem Cell Deficiency (LSCD)?
    • 17.1.2.What Factors Are Constraining the Market for Limbal Stem Cell Deficiency (LSCD)?

18.Appendix

  • 18.1.Methodology
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제